Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
about
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer diseaseVoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.Alzheimer's brains show inter-related changes in RNA and lipid metabolismWhole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults Using 18F-Florbetaben.Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report.Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.Imaging Alzheimer's disease pathophysiology with PET.Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.In vivo quantification of neurofibrillary tangles with [F]MK-6240Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review
P2860
Q33644324-8BCAAFFA-DE50-43C8-8E64-6F02B92FE8FFQ37004909-E07DFFC6-FAFE-42E2-A8EF-7B0035FB8AB6Q37731710-C716675D-2EB4-4405-BDE8-C6276B6928D2Q41566620-27023695-C7A3-466A-88CF-70B3A3D2A664Q41654331-8F62EECB-B8C3-4747-9EDA-9CB40B8ECCD6Q47094913-44809BEA-8EA0-4769-86D6-C246A1B25800Q47152383-B50601D1-A979-4AA5-862C-27B19111A858Q47200597-695ADD58-714A-46F2-B9E1-FDF09021DA83Q47324557-41B8059D-58E5-4CD8-9AE2-2BBB08BF3A6AQ47624462-E6AC8147-30F5-4E91-929D-9B37F38FFC21Q47641780-D890E3D7-05CD-4DD2-B6FB-E68286EC9E1FQ49357063-72A3D674-9625-497A-B096-4090E72BB321Q50042212-7DFF03EA-AF79-494B-BE7C-5995EE4C4271Q50044294-A0E6DEAE-A13C-4F6D-8913-72D37C161055Q50583370-7FCF2FFD-EE70-44D3-9606-923E79637FA4Q51765788-A6384FFC-28CA-4759-9248-7372038A243EQ57040143-EA455ACB-7E2C-4B80-B70C-20D67A63E1C0Q58549216-9BE3D5A1-F0DB-4489-B2CD-EEC839459B1E
P2860
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@en
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@nl
type
label
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@en
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@nl
prefLabel
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@en
Amyloid-β and hyperphosphoryla ...... eclinical Alzheimer's disease.
@nl
P2093
P2860
P356
P1433
P1476
Amyloid-β and hyperphosphoryla ...... reclinical Alzheimer's disease
@en
P2093
A L Benedet
S Gauthier
S Mathotaarachchi
P2860
P2888
P304
P356
10.1038/MP.2016.37
P407
P577
2016-03-29T00:00:00Z